The Manufacturers Life Insurance Company Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

The Manufacturers Life Insurance Company decreased its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,386,602 shares of the medical equipment provider’s stock after selling 167,430 shares during the period. The Manufacturers Life Insurance Company’s holdings in Hologic were worth $172,050,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC boosted its stake in Hologic by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider’s stock worth $412,159,000 after purchasing an additional 144,838 shares during the period. Victory Capital Management Inc. lifted its stake in Hologic by 0.5% in the 4th quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after buying an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Hologic by 3.0% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider’s stock valued at $322,272,000 after buying an additional 129,035 shares in the last quarter. Invesco Ltd. lifted its stake in Hologic by 16.4% in the 4th quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider’s stock valued at $293,434,000 after buying an additional 572,187 shares in the last quarter. Finally, Boston Partners lifted its stake in Hologic by 81.0% in the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.1 %

Shares of Hologic stock opened at $58.08 on Tuesday. Hologic, Inc. has a 12-month low of $55.89 and a 12-month high of $84.67. The company has a market cap of $13.03 billion, a price-to-earnings ratio of 18.32, a PEG ratio of 2.14 and a beta of 0.82. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company’s 50-day moving average price is $60.90 and its 200-day moving average price is $69.77.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on HOLX shares. Citigroup reduced their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Stephens restated an “overweight” rating and set a $84.00 price objective on shares of Hologic in a report on Thursday, February 6th. Raymond James reaffirmed an “outperform” rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.